Pulse Biosciences Inc
$ 42.41
10.90%
07 Aug - close price
- Market Cap 3,024,792,000 USD
- Current Price $ 42.41
- High / Low $ 45.90 / 37.40
- Stock P/E N/A
- Book Value 0.97
- EPS -1.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -0.81 %
- 52 Week High 45.90
- 52 Week Low 12.56
About
Pulse Biosciences, Inc. is a bioelectrical medicine startup. The company is headquartered in Hayward, California.
Analyst Target Price
$32.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-04 | 2026-02-19 | 2025-11-05 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-10-30 | 2024-08-12 | 2024-05-07 | 2024-03-28 | 2023-11-13 |
| Reported EPS | -0.36 | -0.2414 | -0.18 | -0.29 | -0.28 | -0.2502 | -0.3124 | -0.2076 | -0.1991 | -0.18 | -0.2167 | -0.19 |
| Estimated EPS | -0.31 | -0.22 | -0.21 | -0.31 | -0.26 | None | -0.24 | -0.24 | -0.2 | -0.24 | -0.24 | -0.22 |
| Surprise | -0.05 | -0.0214 | 0.03 | 0.02 | -0.02 | 0 | -0.0724 | 0.0324 | 0.0009 | 0.06 | 0.0233 | 0.03 |
| Surprise Percentage | -16.129% | -9.7273% | 14.2857% | 6.4516% | -7.6923% | None% | -30.1667% | 13.5% | 0.45% | 25% | 9.7083% | 13.6364% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLSE
2026-08-08 07:11:30
Pulse Biosciences reported Q2 revenue of $434,000, driven by the acceleration of its nanosecond pulsed field ablation (nsPFA) technology for atrial fibrillation. The company's U.S. NANOPULSE-AF pivotal study is ahead of schedule, with enrollment expected to complete in early October, and it is also advancing its surgical clamp and Vybrance thyroid programs. Despite a widening GAAP net loss of $24.7 million due to increased clinical spending, Pulse Biosciences raised $57.5 million in net proceeds through its at-the-market program, extending its operating runway through planned clinical and regulatory milestones.
2026-08-08 06:10:06
Wall Street Zen has downgraded Pulse Biosciences (NASDAQ:PLSE) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $32.33. The company's stock opened at $42.41, up 10.9%, but it missed analyst expectations for its last quarterly earnings, reporting a loss of $0.36 per share and revenue of $0.43 million. Insiders currently own 74% of the stock, while institutional investors hold 76.95%.
2026-08-07 19:10:06
Pulse Biosciences reported Q2 revenue of $434,000 and is accelerating clinical development of its nsPFA technology, particularly for atrial fibrillation treatment. The company's U.S. NANOPULSE-AF pivotal study is ahead of schedule, with increased enrollment targets and broadened patient eligibility. Despite widening losses due to increased clinical spending, the company's cash and cash equivalents rose to $101.6 million, supported by recent financing efforts.
2026-08-07 19:10:06
Pulse Biosciences announced its business updates and financial results for the second quarter ended June 30, 2026, highlighting significant progress in its cardiac catheter program. The company surpassed the halfway point of enrollment in its U.S. pivotal NANOPULSE-AF study, raising $46.8 million in net proceeds through an ATM program. Total revenue for the quarter was $0.4 million, with a GAAP net loss of ($24.7) million.
2026-08-07 19:10:06
This article announces the filing of a Form 8K by Pulse Biosciences Inc. on August 6th. The brief notice from Investing.com indicates that the information pertains to the company's financial activities or significant events as required by the SEC.
2026-08-07 07:41:15
Pulse Biosciences (PLSE) reported a Q2 loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and underperforming the previous year's loss of $0.28 per share. The company also missed revenue estimates, posting $0.43 million against a 38% higher Zacks Consensus Estimate. Despite the Q2 misses, PLSE shares have seen a significant 176% increase year-to-date, significantly outperforming the S&P 500's 12.8% gain.
